In Vivo Efficacy
Indications Discovery
Specialized Animal Models
Drug Repositioning
Andrew Reaume, PhD, CEO Melior Discovery
Trusted by the Top Leaders in Pharmacology
Melior Discovery's founding mission is drug repositioning - that is finding new uses for existing drugs.
State-of-the-art Preclinical Pharmacology Support
– Richard DiMarchi, PhD
Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry
State-of-the-art Preclinical Pharmacology Support
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry
Phenotypic screening uncovers otherwise
unpredicted new uses for a drug
Learn about our in vivo services
contract research capabilities in most therapeutic areas.
Melior has pioneered a phenotypic
screening platform (theraTRACE® ) suited for in vivo services, drug repositioning, or for identifying novel indications from development-stage candidates.
Serving our community since 2005
Thousands of studies
Hundreds of compounds evaluated
Dozens of animal models of human disease
Our Drug Discovery Philosophy
Recent Studies using Phenotypic Screening
Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation.
Parafati M, Bae SH, Kirby RJ, Fitzek M, Iyer P, Engkvist O, Smith DM, Malany S
Non-alcoholic fatty liver disease (NAFLD) has a large impact on global health. At the onset of disease, NAFLD is charact...
Modelling and phenotypic screening of NAP-6 and 10-Cl-BBQ, AhR ligands displaying selective breast cancer cytotoxicity in vitro.
Baker JR, Pollard BL, Lin AJS, Gilbert J, Paula S, Zhu X, Sakoff JA, McCluskey A
To exploit the interaction of the aryl hydrocarbon receptor (AhR) pathway in developing breast cancer specific cytotoxic...